LDL Cholesterol: The Lower the Better

Medical Clinics of North America

Volumn 96, Issue 1, 2012, Pages 13-26

  Martin, Seth S ^a   Blumenthal, Roger S ^a   Miller, Michael ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Coronary risk; Low density lipoprotein cholesterol; Statins

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ATORVASTATIN; CHOLESTEROL; CYCLOSPORIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FIBRINOLYTIC AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; NEFAZODONE; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PYRROLE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN; VERAPAMIL;

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; CREATINE KINASE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEART INFARCTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MORTALITY; MYALGIA; MYOPATHY; MYOSITIS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DISEASE; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; SUICIDE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, LDL; GUIDELINES AS TOPIC; HUMANS; HYPOLIPIDEMIC AGENTS; INFANT, NEWBORN; LIPID METABOLISM; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PLAQUE, ATHEROSCLEROTIC; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS;

EID: 84863393675     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.01.009     Document Type: Review

References (46)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
3. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:480-486.
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351-364.
5. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365-374.
6. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
7. O'Keefe J.H., Cordain L., Harris W.H., et al. Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J Am Coll Cardiol 2004, 43:2142-2146.
8. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991, 88:1785-1792.
9. Greenland P., Knoll M.D., Stamler J., et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003, 290:891-897.
10. Kannel W.B., Castelli W.P., Gordon T., et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971, 74:1-12.
11. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992, 152:56-64.
12. Pearson T.A., LaCroix A.Z., Mead L.A., et al. The prediction of midlife coronary heart disease and hypertension in young adults: the Johns Hopkins multiple risk equations. Am J Prev Med 1990, 6:23-28.
13. Berenson G.S., Srinivasan S.R., Bao W., et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998, 338:1650-1656.
14. Kuklina E.V., Yoon P.W., Keenan N.L. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA 2009, 302:2104-2110.
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
16. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995, 345:1274-1275.
17. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
18. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349-1357.
20. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
21. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
22. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
23. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
24. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
25. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
26. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
27. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
28. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
29. Crouse J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297:1344-1353.
30. Nicholls S.J., Ballantyne C.M., Barter P.J., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087.
31. Campbell C.Y., Rivera J.J., Blumenthal R.S. Residual risk in statin-treated patients: future therapeutic options. Curr Cardiol Rep 2007, 9:499-505.
32. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
33. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
34. Mikhailidis D.P., Lawson R.W., McCormick A.L., et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011, 27:1191-1210.
35. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
36. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
37. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
38. Kashani A., Phillips C.O., Foody J.M., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788-2797.
39. Nichols G.A., Koro C.E. Does statin therapy initiation increase the risk for myopathy? an observational study of 32,225 diabetic and nondiabetic patients. Clin Ther 2007, 29:1761-1770.
40. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790.
41. Athyros V.G., Tziomalos K., Gossios T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010, 376:1916-1922.
42. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
43. Dale K.M., Coleman C.I., Henyan N.N., et al. Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74-80.
44. Muldoon M.F., Barger S.D., Ryan C.M., et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000, 108:538-546.
45. Hsia J., MacFadyen J.G., Monyak J., et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011, 57:1666-1675.
46. McKenney J.M., Davidson M.H., Jacobson T.A., et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006, 97:89C-94C.